Literature DB >> 3123390

Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens.

J W Murphy1, R L Mosley, R Cherniak, G H Reyes, T R Kozel, E Reiss.   

Abstract

We compared a cryptococcal culture filtrate antigen referred to as CneF with chemically defined cryptococcal antigen fractions isolated by Cherniak and co-workers by using double immunodiffusion gels, polyacrylamide gel electrophoresis, immunoblots, and footpad reactivity of immunized mice. The three previously described components of cryptococcal culture filtrates are a high-molecular-weight glucuronoxylo-mannan (GXM), which is the major constituent, a galactoxylomannan (GaIXM), and a mannoprotein (MP). In this study we demonstrated that CneF contained components which were serologically and electrophoretically similar to the three previously described cryptococcal culture filtrate fractions. The MP fraction elicited significantly stronger delayed-type hypersensitivity responses than did the GXM or GaIXM fraction when used in mice immunized either with the CneF in complete Freund adjuvant or whole heat-killed Cryptococcus neoformans yeast cells. These findings were confirmed when the footpads of immunized mice were challenged with GaIXM and MP preparations from a culture filtrate of a C. neoformans acapsular mutant that does not produce GXM. Thus, we concluded that the MP was the primary component recognized by the anticryptococcal cell-mediated immune response in mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123390      PMCID: PMC259299          DOI: 10.1128/iai.56.2.424-431.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  The antigenic composition of Cryptococcus neoformans. II. Serologic studies with the capsular polysaccharide.

Authors:  E E EVANS; J F KESSEL
Journal:  J Immunol       Date:  1951-08       Impact factor: 5.422

2.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

3.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

4.  Anticryptococcal type D antibodies raised in rabbits.

Authors:  A K Bhattacharjee; J E Bennett; D R Bundle; C P Glaudemans
Journal:  Mol Immunol       Date:  1983-04       Impact factor: 4.407

5.  Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans.

Authors:  E Reiss; R Cherniak; R Eby; L Kaufman
Journal:  Diagn Immunol       Date:  1984

6.  Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans.

Authors:  S H Turner; R Cherniak; E Reiss
Journal:  Carbohydr Res       Date:  1984-02-15       Impact factor: 2.104

7.  Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans.

Authors:  E S Jacobson; D J Ayers; A C Harrell; C C Nicholas
Journal:  J Bacteriol       Date:  1982-06       Impact factor: 3.490

8.  Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen.

Authors:  J W Murphy; J W Moorhead
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

9.  Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

Authors:  R Ikeda; T Shinoda; Y Fukazawa; L Kaufman
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

10.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

View more
  48 in total

1.  Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction.

Authors:  K L Buchanan; J W Murphy
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.

Authors:  Rebecca Blackstock
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

Review 3.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

4.  Localization of mannoprotein in Cryptococcus neoformans.

Authors:  S E Vartivarian; G H Reyes; E S Jacobson; P G James; R Cherniak; V R Mumaw; M J Tingler
Journal:  J Bacteriol       Date:  1989-12       Impact factor: 3.490

5.  Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens.

Authors:  W Gade; S W Hinnefeld; L S Babcock; P Gilligan; W Kelly; K Wait; D Greer; M Pinilla; R L Kaplan
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

6.  Mechanisms for induction of L-selectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan.

Authors:  Z M Dong; L Jackson; J W Murphy
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

7.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

8.  Galactoxylomannans of Cryptococcus neoformans.

Authors:  P G James; R Cherniak
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

9.  Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses.

Authors:  Chao Huang; Shu-Hua Nong; Michael K Mansour; Charles A Specht; Stuart M Levitz
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Protective efficacy of antigenic fractions in mouse models of cryptococcosis.

Authors:  Michael K Mansour; Lauren E Yauch; James B Rottman; Stuart M Levitz
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.